CD274 and non-small cell lung carcinoma: This study randomized 1274 EGFR and ALK WT, locally advanced or metastatic NSCLC patients with PD-L1 ≥ 1% to either pembrolizumab, 200 mg every three weeks for up to two years, or platinum-based chemotherapy for 4–6 cycles.